Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darren H Wakefield

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Bioconjugate Chemistry|September 22, 2005
Membrane activity and transfection ability of amphipathic polycations as a function of alkyl group sizeDarren H Wakefield, Jason J Klein, Jon A Wolff, et al.
Nucleic Acids Research|February 10, 2017
Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analysesVladimir S Trubetskoy, Jacob B Griffin, Anthony L Nicholas, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2007
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytesDavid B Rozema, David L Lewis, Darren H Wakefield, et al.
Molecular Cancer Therapeutics|October 29, 2017
HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell CarcinomaSo C Wong, Weijun Cheng, Holly Hamilton, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 27, 2013
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infectionChristine I Wooddell, David B Rozema, Markus Hossbach, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 19, 2015
Protease-triggered siRNA delivery vehiclesDavid B Rozema, Andrei V Blokhin, Darren H Wakefield, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Bioconjugate Chemistry|September 22, 2005
Membrane activity and transfection ability of amphipathic polycations as a function of alkyl group sizeDarren H Wakefield, Jason J Klein, Jon A Wolff, et al.
Nucleic Acids Research|February 10, 2017
Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analysesVladimir S Trubetskoy, Jacob B Griffin, Anthony L Nicholas, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2007
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytesDavid B Rozema, David L Lewis, Darren H Wakefield, et al.
Molecular Cancer Therapeutics|October 29, 2017
HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell CarcinomaSo C Wong, Weijun Cheng, Holly Hamilton, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 27, 2013
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infectionChristine I Wooddell, David B Rozema, Markus Hossbach, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 19, 2015
Protease-triggered siRNA delivery vehiclesDavid B Rozema, Andrei V Blokhin, Darren H Wakefield, et al.
Pageof 1